Clinical Trial

Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
multicenter, open label, randomaized, phase III The role of post surgery adjuvant chemotherapy is becoming more and more important in AGC (advance gastric cancer). S-1 and combined therapy of Capecitabine and Oxaliplatin are currently accepted as a standard therapy among the AGC patients who were performed gastrectomy from the D2 surgery. However, many improvements will be needed in stage IIIB and IV. Combined chemotherapy of Docetaxel, Capecitabine, and Oxaliplatin may be considered as one of the best treatments for IIB and IV(M0) stage AGC patients who were performed gastrectomy.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2013-09-01; most recent amendment 2024-02-27.
Status change: Not Yet Recruiting → Recruiting 2014-03-27
Trial Details
NCT Number NCT01935778
Lead Sponsor Asan Medical Center
Collaborators: Seoul National University Bundang Hospital, Severance Hospital, Inha University Hospital, Hallym University Medical Center
Conditions Gastric Cancer, Adjuvant Chemotherapy, XO
Enrollment 286 participants
Start Date 2013-10-02
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-02-28